公开(公告)号：US20230138414A1

公开(公告)日：2023-05-04

申请号：US18073181

申请日：2022-12-01

申请人： The Trustees of Columbia University in the City of New York

发明人： Andrei V. Tkatchenko ,  Tatiana V. Tkatchenko

IPC分类号： A61K31/451 ,  A61K31/137 ,  A61K31/165 ,  A61K31/4375 ,  A61K31/198 ,  A61P27/10

摘要： The disclosure relates to methods and compositions for preventing and/or treating an ocular disease. In particular, the disclosure relates to preventing and/or treating myopia with systemic or topical administration of an active drug compound including levocabastine hydrochloride, which is a selective histamine H1-receptor antagonist; fenoterol hydrobromide, which is a β2-adrenergic receptor agonist; trichostatin A, which is a histone deacetylase (HDAC) inhibitor; fingolimod (FTY720) phosphate, which is a sphingosine-1-phosphate receptor modulator; berberine chloride, which is a berberidaceaen alkaloid; S-methyl-L-thiocitrulline hydrochloride, which is a selective neuronal nitric oxide synthase (nNOS) inhibitor; and derivatives thereof.

公开(公告)号：US11524032B2

公开(公告)日：2022-12-13

申请号：US16960077

申请日：2019-01-07

申请人： University of Utah Research Foundation

发明人： Randon Michael Burr ,  Balamurali K. Ambati ,  Sarah A. Molokhia

IPC分类号： A61K33/34 ,  A61P27/10 ,  A61K9/00 ,  A61K45/06

摘要： An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.

公开(公告)号：US20220160623A1

公开(公告)日：2022-05-26

申请号：US17364470

申请日：2021-06-30

申请人： Allergan, Inc.

发明人： Mohammed Dibas ,  Daniel W. Gil ,  Wayne Chen ,  Miguel Alcantara

IPC分类号： A61K9/00 ,  A61P27/02 ,  A61P27/10 ,  A61K31/4178

摘要： Methods of using the alpha-2-adrenergic receptor agonist of Formula I: for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.

公开(公告)号：US11306090B2

公开(公告)日：2022-04-19

申请号：US16760192

申请日：2018-11-02

申请人： Alcon Inc.

发明人： David Ellis ,  Howard Allen Ketelson

IPC分类号： C07D471/08 ,  A61P27/10 ,  A61K9/00 ,  C07D243/38 ,  C07D471/04

摘要： The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.

公开(公告)号：US11285141B2

公开(公告)日：2022-03-29

申请号：US16632105

申请日：2018-07-20

申请人： Seinda Pharmaceutical Guangzhou Corporation

发明人： Hui Ouyang ,  Yong Qiu

IPC分类号： A61K31/46 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/551 ,  A61K31/498 ,  A61K31/24 ,  A61K31/465 ,  A61K31/496 ,  A61K31/443 ,  A61K31/4025 ,  A61K31/4409 ,  A61K31/5513 ,  A61K31/222 ,  A61K9/00 ,  A61K45/06 ,  A61P27/02 ,  A61P27/10

摘要： Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

公开(公告)号：US11253507B2

公开(公告)日：2022-02-22

申请号：US16487423

申请日：2018-02-20

申请人： Singapore Health Services PTE LTD

发明人： Donald Tiang Hwee Tan ,  Audrey Chia ,  Roger Beuerman ,  Amutha Barathi Veluchamy

IPC分类号： A61K31/46 ,  A61P27/10 ,  A61K9/00 ,  A61K47/18 ,  A61K47/38

摘要： Methods of preventing or delaying onset of myopia in pre-myopic patients and also methods of reducing or preventing progression of myopia in patients having low myopia through the use of compositions comprising less than 0.025% of atropine are disclosed.

公开(公告)号：US11008385B2

公开(公告)日：2021-05-18

申请号：US15558139

申请日：2016-03-15

申请人： Shefali Brinda Jonas ,  Rahul Arvo Jonas ,  Jost B. Jonas ,  Songhomitra Panda-Jonas

发明人： Shefali Brinda Jonas ,  Rahul Arvo Jonas ,  Jost B. Jonas ,  Songhomitra Panda-Jonas

IPC分类号： A61K38/18 ,  C07K16/22 ,  C07K14/485 ,  A61P27/10 ,  C07K16/28 ,  C07K14/71 ,  G01N33/68

摘要： The present invention relates to agents for use in the prophylactic or therapeutic treatment of myopia in a subject, wherein said agents are capable of decreasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject in a direct or indirect manner. The present invention further relates to agents for use in the prophylactic or therapeutic treatment of hyperopia in a subject, wherein said agents are capable of increasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject. Furthermore, the present invention relates to methods for the diagnosis of myopia or hyperopia in a subject, comprising the steps of (a) providing a biological sample from the subject; (b) determining the amphiregulin level in said sample; (c) comparing the level determined in step (b) to the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and (d) determining that the subject has myopia or is predisposed for the development of myopia in case the level determined in step (b) is higher than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and determining that the subject has hyperopia or is predisposed for the development of hyperopia in case the level determined in step (b) is lower than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic. Finally, the present invention relates to a method for identifying agents which associate with amphiregulin or fragments or variants thereof.

公开(公告)号：US10993932B2

公开(公告)日：2021-05-04

申请号：US16841026

申请日：2020-04-06

申请人： Ocuphire Pharma, Inc.

发明人： William H. Pitlick ,  Alan R. Meyer ,  Mina Sooch ,  Konstantinos Charizanis ,  Bernhard Hoffmann

IPC分类号： A61K31/415 ,  A61K31/417 ,  A61P27/08 ,  A61P27/10 ,  A61K31/4178 ,  A61K9/00 ,  A61K9/08 ,  A61K47/12 ,  A61K47/26

摘要： The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.

公开(公告)号：US20200253931A1

公开(公告)日：2020-08-13

申请号：US16841026

申请日：2020-04-06

申请人： Ocuphire Pharma, Inc.

发明人： William H. Pitlick ,  Alan R. Meyer ,  Mina Sooch ,  Konstantinos Charizanis ,  Bernhard Hoffmann

IPC分类号： A61K31/417 ,  A61K31/4178 ,  A61P27/10

摘要： The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.

公开(公告)号：US20190000755A1

公开(公告)日：2019-01-03

申请号：US16106730

申请日：2018-08-21

申请人： Presbyopia Therapies, LLC

发明人： Gerald Horn ,  Lee Nordan

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K47/26 ,  A61K45/06 ,  A61K31/439 ,  A61P27/10 ,  A61K31/4409 ,  A61K47/32 ,  A61K47/38

摘要： The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.